MMB8036 : Therapy Development for Rare Diseases: the neuromuscular paradigm
- Offered for Year: 2019/20
- Module Leader(s): Dr Michela Guglieri
- Lecturer: Dr Anna Mayhew, Ms Becca Leary, Dr Alison Blain, Professor Volker Straub, Mr Jan Deckers, Miss Liz Greally
- Visiting Lecturer: Dr Anna Sarkozy
- Owning School: FMS Graduate School
- Teaching Location: Newcastle City Campus
|Semester 1 Credit Value:||20|
This module will provide key background information on normal muscle physiology and neuromuscular structure and function. It will continue into detailed discussion of the neuromuscular diseases, and the impact that these rare conditions have on muscle structure and function. The challenges and promise of novel therapeutic strategies for neuromuscular diseases, including gene and cell-based approached, will be a key focus of the module, which emphasises the 'bench to bedside' approach of translating laboratory findings into therapeutic interventions. Specific aims will be:
1. To educate students in the development of therapy for rare diseases, using neuromuscular diseases as an example of a growing field of research.
2. To explore the challenges and promise of genetic modifying therapies and gene therapy.
3. To develop students' understanding of the role of cellular and animal models in moving therapies into practice and the design of preclinical experiments.
4. To explore the challenges in drug development and clinical trial designs in rare diseases and how these can be addressed.
5. To introduce the students to ethical issues related to drug development and national and international regulatory requirements.
Outline Of Syllabus
The module will start with an introduction to neuromuscular diseases as an example of rare diseases. This will include normal muscle structure and function, including normal muscle physiology, how neuromuscular diseases impact on this and the clinical and electrophysiological manifestations of muscle dysfunction across the neuromuscular system. The module will then go on to cover:
1. How to define the target for clinical research: identify the molecular pathology of neuromuscular diseases to understand heterogeneity and identify potential therapeutic targets.
2. Model systems to study diseases: uses and limitations of cell cultures, zebra fish, mouse and other animal models to understand disease pathology and test therapeutic approaches. This includes an overview of existing models, methodology to develop new models and a critical appraisal of claims of therapeutic success in the preclinical setting.
3. Drug development in rare diseases: the different phases of clinical trials; discussion on clinical trial designs, clinical and biochemical outcome measures, their current use and future applications with examples from current pre-clinical studies and clinical trials.
4. The state of the art novel therapeutic strategies for neuromuscular diseases including: gene and cell based therapies; understanding the targets and use of biomarkers; genetic therapy for neuromuscular diseases applications of antisense oligonucleotide technology in neuromuscular diseases; other targets for therapy development including downstream targets and protein up regulation; pros and cons of clinical research on repurposing drugs.
5. Regulatory requirements and ethical issues in drug development for rare diseases.
6. The importance of international collaborations and examples of global networks and infrastructures to facilitate clinical research.
During the module, students will have the opportunity to meet patients with different neuromuscular diseases and will also have the opportunity to learn to critically assess preclinical research. This will be in the form of a session during which students will be provided with a fictional application from a company planning a clinical trial in a specified neuromuscular disease. Students will be encouraged to identify and discuss the strengths and limitations of the application.
|Scheduled Learning And Teaching Activities||Lecture||17||1:00||17:00||Delivery of information to meet knowledge outcomes through a series of lectures given by specialists|
|Guided Independent Study||Assessment preparation and completion||1||32:00||32:00||Preparation for group exercise|
|Scheduled Learning And Teaching Activities||Practical||1||1:00||1:00||Mock sessions on study designs.|
|Scheduled Learning And Teaching Activities||Small group teaching||1||2:00||2:00||Ethical debates and problems in rare disease translational research|
|Scheduled Learning And Teaching Activities||Small group teaching||2||4:00||8:00||Experimental design and critical analysis of literature as preparation for assessed presentations|
|Guided Independent Study||Independent study||1||140:00||140:00||N/A|
Teaching Rationale And Relationship
The series of lectures will deliver the key information to meet knowledge outcomes, and guided reading will reinforce and develop this knowledge. Small group teaching sessions allow for interactive discussion and preparation around data analysis and experimental design. The practical session delivers a session to critically assess a mock example of preclinical research.
The format of resits will be determined by the Board of Examiners
|Written Examination||60||1||A||50||One essay question from a choice of three|
|Written exercise||1||M||10||MCQ test on the content of the assessed presentations|
|Prob solv exercises||1||M||20||Group exercise and presentation, as teams on specific disease groups,providing analysis of molecular pathology of a nominated topic|
|Prob solv exercises||1||M||20||Group exercise and presentation, as teams on specific disease groups,providing analysis of therapeutic options of a nominated topic|
Assessment Rationale And Relationship
• The written exam will test the knowledge of the students as related to all of the stated intended knowledge outcomes of the module.
• The MCQ test will encourage students to access their own and other student presentations and revise them prior to the exam, in addition to review the lecture content.
• The group working and presentations will test individual and group working abilities as well as presentation skills, the ability to put together complex information related to neuromuscular diseases, including experimental design and critical anaysis of related research, and the ability to communicate it effectively to their peers.